Abstract Metabolomic imaging of prostate cancer (PCa) aims to improve in vivo imaging capability so that PCa tumors can be localized noninvasively to guide biopsy and evaluated for aggressiveness prior to prostatectomy, as well as to assess and monitor PCa growth in patients with asymptomatic PCa newly diagnosed by biopsy. Metabolomics studies global variations of metabolites with which malignancy conditions can be evaluated by profiling the entire measurable metabolome, instead of focusing only on certain metabolites or isolated metabolic pathways. At present, PCa metabolomics is mainly studied by magnetic resonance spectroscopy (MRS) and mass spectrometry (MS). With MRS imaging, the anatomic image, obtained from magnetic resonance imaging, is mapped with values of disease condition-specific metabolomic profiles calculated from MRS of each location. For example, imaging of removed whole prostates has demonstrated the ability of metabolomic profiles to differentiate cancerous foci from histologically benign regions. Additionally, MS metabolomic imaging of prostate biopsies has uncovered metabolomic expression patterns that could discriminate between PCa and benign tissue. Metabolomic imaging offers the potential to identify cancer lesions to guide prostate biopsy and evaluate PCa aggressiveness noninvasively in vivo, or ex vivo to increase the power of pathology analysis. Potentially, this imaging ability could be applied not only to PCa, but also to different tissues and organs to evaluate other human malignancies and metabolic diseases.
Introduction
Prostate cancer (PCa) is the second most frequently diagnosed malignancy worldwide, and according to the estimates of the National Cancer Institute, 1 in 4 men in the U.S. will be affected by PCa during his lifetime, where it is also the second leading cause of cancer death in men [1, 2] . The serum prostate-specific antigen (PSA) screening test has greatly increased the incidence of PCa since its introduction to the clinic in the late 1980s, and has shifted the population with diagnosed PCa toward earlier disease stages [3, 4] . While PSA screening has saved lives, it has also created controversies for PCa management as the detection of PCa cannot currently be achieved through targeted biopsies, in general [5] [6] [7] . Thus, random, ineffective biopsies may be performed in the context of small, heterogeneously distributed, early-stage prostate tumors, commonly resulting in false-negative findings referred to as histological sampling errors [8] . In the current PSA screening era, biopsies from patients with early-stage PCa very often appear to be histologically benign tissue samples.
PCa statistics strongly suggest that the vast majority of patients whose PCa has been discovered through PSA screening will likely follow a long and indolent course of development and progression. Many patients with newly diagnosed PCa thus harbor a disease unlikely to ever evolve into a lifethreatening, clinically significant condition. Current histology, however, is limited in characterizing asymptomatic PCa and distinguishing aggressive from indolent, biopsy-detected PCa. This leads to compromised clinical decisions between beneficial therapies and morbidities occasioned by unnecessary overtreatment [1, 9, 10] . A large population of patients with newly diagnosed PCa, wary of the morbidities associated with radical treatments, elect to enter active surveillance, while the supporting empirical data remain very limited. Furthermore, the current inabilities of PCa imaging limit patient monitoring during active surveillance, where patients can only be subjected to periodic invasive prostate biopsies with known sampling errors [11] . At the same time, in order to ensure that the few aggressive cases are not missed, another school of thought encourages radical procedures for a significant population, resulting in unnecessary overtreatment that causes adverse effects and impairs quality of life for many patients with indolent PCa [12] .
Therefore, improving in vivo PCa imaging ability would not only assist PCa detection through imaging-guided biopsies to overcome the currently observed histological sampling error, but also provide an urgently needed noninvasive tool to assess and monitor PCa growth in patients with asymptomatic PCa newly diagnosed by biopsy, undergoing active surveillance. To address these needs, PCa metabolomic imaging has been developed as a unique way to probe the underlying biochemistry of malignancy development and progression. Metabolomics is the study of global variations of metabolites, the intermediates or end-products from cellular biochemical reactions, with which malignant conditions can be evaluated by profiling the entire measurable metabolome, instead of focusing only on certain metabolites or an isolated metabolic pathway [13] .
The concept of metabolomics stems from the holistic approach of genomics and proteomics, from which studies of isolated genes and individual proteins evolved to correlative evaluations between the entire measurable genome and proteome under physiological and pathological conditions. In these studies, and as the model for metabolomics studies, the biological system is analyzed as a whole, providing a more inclusive presentation of cancer progression to assist in disease diagnosis and detection [13] . In PCa research, while studies focusing on changes in individual metabolite levels have proven very valuable in advancing biological understanding of PCa, metabolomic profiles have shown even greater promise for improving PCa diagnosis and monitoring disease progression. Additionally, in comparison with genomics and proteomics, metabolomics has advantages in probing the status of disease conditions for it measures the downstream effects of changes in genes and proteins, thereby integrating the study of all alterations in genetic regulation, enzyme activity, and metabolic reactions into the reflection of the present disease status in terms of measurable biological activities [14] . In this review, we address the role metabolomics plays in the study of PCa and the promise metabolomic imaging holds for improving PCa diagnoses and prognoses in the clinical setting.
PCa metabolomics
At present, the study of PCa metabolomics is mainly accomplished utilizing one of two analytical platforms, nuclear magnetic resonance (NMR) spectroscopy, more commonly referred to as magnetic resonance spectroscopy (MRS), and mass spectrometry (MS). Although numerous studies applying these technologies to prostate cells lines [15, 16] , animal prostate models [17] [18] [19] , and biological fluids from PCa patients including urine, semen, and prostatic fluid [20] [21] [22] [23] , have been reported, in this review, we focus on discussions centered around human prostate tissue samples to emphasize the potential and ultimate goal of immediate translation of PCa metabolomics to the clinical care of PCa patients, including in vivo imaging.
Currently, MRS is as the most realistic option for implementation in the PCa clinic through an avenue known as MRS imaging (MRSI), achievable on MR scanners used in humans. While MRSI based on measured cellular metabolites has been incorporated into practice in a number of clinical centers for human in vivo imaging, most studies of human PCa metabolomics at high spectral resolution (i.e. with optimal identification of individual metabolites) are researched ex vivo using the method of high-resolution magic angle spinning (HRMAS) proton MRS, introduced for intact biological tissue analysis in 1996 [24, 25] . This method applies mechanical rotation of the sample at an angle of 54.7°to the magnetic field, providing high-resolution spectra and allowing the observation of individual metabolites. A key advantage of the method is its preservation of tissue architectures, thus allowing subsequent histopathology analysis of the same tissue specimen [26, 27] .
Since the initial application of the HRMAS method, studies have found that quantification of individual metabolite levels and metabolite ratios, as well as metabolomic profiles, show strong potential to improve accuracy in PCa detection, diagnosis and monitoring of disease progression. While metabolomic profiles have been shown to provide an enhanced capacity in the diagnosis and monitoring of PCa, there are many findings from studies focusing on individual metabolites in prostate tissue using HRMAS that have proven very valuable in advancing our understanding of PCa. The metabolites spermine, a polyamine abundant in the prostate and a proposed endogenous inhibitor of PCa growth [28] , and citrate, a critical prostate metabolite related to zinc depletion in malignant prostate tissue [29] , have both been found to correlate with the volume percentage of histologically benign prostatic epithelial cells, while the latter also correlates with PSA velocity, PSA density, and serum percent free PSA [30] . Other studies have found phosphocholine, taurine, myo-inositol, scyllo-inositol, lactate, and alanine concentrations to be significantly higher, and ethanolamine concentrations, significantly lower, in PCa tissue than in benign tissue [31] [32] [33] .
While the studies of individual metabolites have uncovered much about the biochemical changes taking place during PCa development and progression, they do not provide a holistic picture of the malignant status, and therefore, to better evaluate the overall status, a metabolomic approach has been tested as a superior method for assisting in PCa detection and predicting pathological stage and recurrence potential. A critical study that illuminated the strength of metabolomic profiles over individual metabolites, as well as histopathology evaluations alone, is that of Cheng et al. [34] . Metabolomic profiles obtained from principal component analysis and canonical analysis of HRMAS proton MRS of 199 samples from 82 PCa patients were correlated with pathological status. These profiles were able to differentiate cancerous and histologically benign samples from the same patients with 98.2 % accuracy (Fig. 1) . Most importantly, due to the advantage of the preservation of tissue pathology with HRMAS, 179 of these 199 samples were found to be histologically benign tissue samples from PCa patients. However, metabolomic profiles calculated from these histologically benign tissue samples were able to differentiate pathological cancer stage T2ab cancer (prostate-confined to one of the two lobes) from T2c (prostateconfined but extended to both lobes, p <0.002) and T3 cancer (invading extraprostatic tissue, p<0.00002; Fig. 2 ). Furthermore, metabolomic profiles calculated from these samples were able to delineate a subset of less aggressive (Gleason score (GS) 6 and T2ab) tumors and predict tumor perineural invasion, an indicator of tumor aggressiveness, within the subset [34] . The discovery of these metabolomic field effects, such that histologically benign prostate tissue from a cancerous prostate can reveal PCa status, presents a real promise for rectifying the current issue of histological sampling error. In a study discussed below, metabolomic profiles obtained from relative spectral intensities (normalized to the spectral region 0.5-4.5 ppm) in the same patient population were also able to differentiate cancerous samples from histologically benign ones with 93 % accuracy [35] .
Metabolomic profiles calculated from intact tissue HRMAS proton MRS can also be used to assess PCa biochemical recurrence potential, defined as the detection of serum PSA elevations after radical prostatectomy. A retrospective study evaluated 16 patients with PCa recurrence paired with clinically and pathologically stage-matched patients without recurrence. From the MRS results in these 48 individuals, the 27 most common and intense spectral metabolic regions were identified to calculate the metabolomic profiles. Applying the metabolomic profiles obtained from the clinical stage-matched group (training cohort) to the pathological stage-matched group (testing cohort) revealed an ability to predict cancer recurrence potential with an overall accuracy of 78 % [36] . Since empirical clinical evaluations cannot further subcharacterize these matched groups, an accuracy of greater than 50 % has the possibility to improve the ability of the current PCa clinic to predict recurrence potential.
The significant advantage of MRS-based metabolomic studies of human PCa is its potential for in vivo translation. The ultimate goal of PCa metabolomics is to improve in vivo imaging capability so that PCa tumors can be localized before biopsy to reduce the occurrence of histological sampling error and the number of false-negative biopsies, and also evaluated for aggressiveness and malignant potential so as to better guide treatment. For ex vivo studies, HRMAS has important characteristics that make it a vital method for PCa analysis. The technology provides high-resolution spectra without sacrificing tissue architectures, as is seen in the tissue chemical extract procedures used for solution NMR analyses, and also requires less sample volume and shorter preparation time than solution extraction methods [26] . In addition, the innovation of slow sample spinning rates, followed by various rotorsynchronized spinning side-band suppression methods, allows subsequent uncompromised histopathological analysis, the current gold standard for PCa diagnosis and monitoring, of the same tissue specimen [37, 38] .
Another significant area of PCa metabolomics has been developed with MS. While MS requires an initial separation of metabolites by gas or liquid chromatography, and therefore destruction of the tissue histology structures, it has much greater sensitivity and can detect metabolites at much lower concentrations than MRS [14] . Although MS can currently only be used in ex vivo PCa studies and the translation possibility of the technology into in vivo imaging in the clinic is not as likely as with MRS, significant results of PCa metabolomics have been revealed with MS analyses.
Using a combination of high-throughput MS based on gas chromatography and liquid chromatography, Sreekumar et al. detected 626 metabolites from 42 prostate tissue samples, of which 16 were histologically benign, 12 were from patients with clinically localized PCa, and 14 were from patients with metastatic PCa. Of the 626 metabolites, 60 were found in localized and/or metastatic PCa but not in the benign samples. Also, 516 metabolites differentiating between localized PCa and benign samples were determined, of which 50 were increased and 37 downregulated in PCa when compared to benign samples, and 124 were increased and 107 downregulated in metastatic samples when compared to localized PCa samples (Fig. 3) [39] . As a benefit of evaluating altered biochemical pathways from the analysis of the overall differential metabolomic profiles, instead of measuring individual metabolites, the study revealed an increase in amino acid metabolism and nitrogen breakdown pathways during PCa metastatic progression. These findings provide a more robust view of the changes taking place during PCa development and will Histopathological analysis of the tissue sample (inset) after spectroscopy measurement revealed that the sample contained 40 % histopathologically defined benign epithelium and 60 % stromal structures, with no identifiable cancerous glands. Cellular metabolites mentioned in the text are labeled on the spectrum. The 36 most intense resonance peaks or metabolite groups above the horizontal bars were selected for analysis, whereas the other regions were excluded from calculation partly because of surgery-related alcohol contamination. b Three-dimensional plot of principal component 13 (PC13 correlates linearly with percent volume of cancer cells in tissue samples) versus phosphocholine versus choline. Cancerous and histologically benign (Histo-benign) tissue samples from 13 patients can be visually separated. The paired Student's t test results (cancer versus histologically benign from the same patients) for principal component 13, phosphocholine, and choline were; p = 0.012, p = 0.004, and p = 0.001, respectively. Only results from these 13 patients could be evaluated with paired tests for other cancer-positive samples were collected from patients from whom no histologically benign samples were analyzed. c Canonical plot resulting from discriminant analysis of the three variables in b shows the maximum separation between the two groups. d The resulting receiver operating characteristic curve indicates the accuracy of using the three variables in b to positively identify cancer samples (adapted with permission from Cheng et al. [34] , Fig. 1) therefore provide stronger parameters for detection and monitoring.
However, one of the limitations of MS, similar to chemical extraction of tissue samples for solution MRS measurements, is the destruction of the studied specimen in order to extract metabolites for quantification. To address this issue, a new protocol for MS analysis has recently been proposed, the Molecular Preservation by Extraction and Fixation (mPREF) method. Using this method, prostate needle biopsies are fixed in methanol to both extract small molecules and fix the tissue. With this procedure, both histological and immunohistochemical analyses have been shown to be successful following fixation, and 260 metabolites were detected in alcohol extracts by MS. Of these compounds, 82 showed increased levels in extracts from cancer-containing biopsies when compared to extracts from histologically benign biopsies [40] . Although not nearly as many metabolites were quantified as in the study reviewed earlier, the preservation of prostate tissue for subsequent histopathological analysis is an important development in the progress of PCa metabolomics using MS. While MS may never be compatible with in vivo imaging, it does provide a realistic option for an additional pathological measure for clinical prostate biopsy samples.
Metabolomic imaging
The proposal of the concept of PCa metabolomics is inspired by the developments of genomics and proteomics. However, the development of MRS-based PCa metabolomic imaging has only been feasible with the technical advances in MR technology seen in MR scanners for imaging in humans. Metabolomic imaging utilizes the capacity of MR scanners to acquire localized multivoxel spectroscopy, and maps the anatomic image obtained from MRI with values of disease condition-specific metabolomic profiles calculated from MRS of each voxel. Such a strategy is fundamentally different from commonly practiced MRSI, in which mapping is achieved with intensities of single metabolites to produce a collection of maps reflecting the spatial distributions of metabolite concentrations. However, with a single set of multivoxel MRS, metabolomic imaging can generate a series of distribution maps of disease conditions, rather than distributions of individual metabolites as seen in MRSI.
In vivo MRSI is a noninvasive method that captures spatial metabolic intensities measurable from MRS localized by MRI. However, since metabolites occur in much lower concentrations than water, measurable with MRI, the signal-tonoise ratio (SNR) of metabolites may be improved by applying lipid and water suppression techniques and using larger MRS voxel sizes of about 0.3 cm 3 with 1.5-T scanners, than those used in MRI. The voxel size can be further reduced at higher field strengths, such as to 0.1 cm 3 at 3 T [33, 41, 42] . Close-fitting coils, or endorectal coils in the case of prostate imaging [43] , can also contribute to improved MRS quality.
The most active topic, with the longest investigation history, is MRSI of the brain. Due to the low SNR with metabolites, signal averages are always required for MRS measurements. Thus, in addition to the intrinsic advantage of the absence of adipose connective tissue and the lack of respiratory motion in the brain, the head can be conveniently stabilized with tight-fitting coils during MRSI examination to produce sufficient SNR and high spectral resolution.
Overlaying these high-resolution MRS results with MRI images measured at the same location can produce metabolite maps that reflect disease-related metabolite activities, as illustrated by the results of a human brain tumor study (Fig. 4) . Spatial metabolite maps of choline/N-acetylaspartate ratios acquired with a 3-T MR scanner, as well as lipid and reference water scans, from this study in a patient with an oligodendroglioma are shown. Tumor lesions are characterized by increases in metabolite intensities of choline and decreases in N-acetylaspartate, while the localized metabolite changes coincide with the lesions reflected by hyperintensities on T2-weighted MR imaging [44] .
MRSI studies of the brain can be traced back to the early 1980s when the proof-of-concept of MRSI was reported following studies of intracellular cerebral metabolism of newborn infants by phosphorus MRS. By investigating and comparing cerebral metabolism of healthy and birthasphyxiated newborns, low values of the ratio phosphocreatine/inorganic orthophosphate were correlated with poor prognosis for survival and early neurodevelopmental onset [45, 46] . The methodology has continued to contribute to neurological studies of brain tumors [47] , neurodegenerative diseases [48, 49] , psychiatric disorders [50] [51] [52] , trauma [53] , ischemia [54] , epilepsy [55] , etc., for diagnostics, therapy monitoring and patient follow-up. Fig. 4 Three-dimensional metabolite mapping at 3 T in a patient with a brain tumor. T2-weighted MR images, metabolite maps and water reference scans demonstrate spatial heterogeneity of the lesion. Data were acquired over 10 min including the water reference scan using a 32×32× 8 spatial matrix and 7-mm isotropic voxel dimensions (0.34 cm 3 voxel size) (adapted with permission from Posse et al. [44] , Fig. 10 ) Fig. 5 Data from MRSI and MRI of the prostate directly aligned and overlaid. a A T2-weighted FSE axial image taken from a volume dataset shows a large tumor in the right midgland to base. The selected volume for spectroscopy (bold white box) and a portion of the 16×8×8 spectral phase-encoded grid from one of eight axial spectroscopic slices is shown overlaid (fine white line) on the T2-weighted image. Spectra in regions of cancer (b red box) demonstrate dramatically elevated choline, and a reduction or absence of citrate and polyamines relative to regions of healthy peripheral zone tissue (c green box). In this fashion, metabolic abnormalities can be correlated with anatomical abnormalities throughout the prostate. The strength of the combined MRI/MRSI examination is demonstrated when changes in all three metabolic markers (choline, polyamines, and citrate) and imaging findings are concordant for cancer (adapted with permission from Kurhanewicz et al. [56] , Fig. 2 ) Fig. 6 Metabolomic imaging of cancer from an excised human prostate. a Axial MR image of a prostate cross-section (from a 47-year-old patient with TNM stage pT2cNxMx) overlaid with a grid to indicate the locations of 16×16 voxels for which multivoxel MR spectra were acquired. The outer white border delineates the outline of the prostate cross section; the inner white border encloses the urethra. Spectra of voxels outside the outer border and inside the inner border were not included in the analysis. b Because of the susceptibility to magnetic interference at the tissue-air interface, spectra from voxels between the solid and dashed lines were eliminated from further analysis. The values of the metabolomic profile for the remaining voxels were calculated for all remaining voxels. The values were then mapped onto the MR image with a color range calibrated to −100 to 100. c Histologically identified cancer regions are circled in red and plotted onto a whole-mount prostate histology image at approximately the same prostate cross-sectional level as in b. Metabolomic profile regions having at least two connected voxels with profile values greater than M+SD are plotted and shown in red. Partial tumor sizes are estimated by excluding their overlaps (purple voxels). Here, the "partial tumor size" for the right lesion on the top right of the histological slide equals the total tumor size, whereas for the cancer region on the top left of the histological slide it is less than half the tumor size. Geometrical centers are used to calculate the center of profile-elevated regions and to estimate the center of partial tumor size, excluding the discarded voxels. d Representative spectra from voxels with elevated (a in b) and nonelevated (b in b) profile values are plotted (adapted with permission from Wu et al. [35] , Fig. 3) The success of MRSI in studies of the brain encouraged its exploration for imaging of human PCa. An important study is that of Kurhanewicz et al. in 1996 who applied MRSI to the evaluation of PCa on a 1.5-T scanner with an endorectal coil. Using the intensities from single metabolites and metabolite ratios, the existence and spatial extent of PCa was defined [57] . Since then MRSI has become a tool attracting growing interest in PCa studies. At 1.5 T, MRSI has been shown to discriminate healthy from cancerous prostate tissue with an overall accuracy of 81 % when tissue samples were selected from a group of patients with biopsy-proven PCa for postsurgical HRMAS proton MRS measurements [33] . MRSI has further demonstrated its potential to guide biopsy including directing the biopsy towards the most aggressive part of the tumor, as well as detecting residual or recurrent cancer lesions [58] [59] [60] [61] .
Additionally, MRSI has shown potential in identifying tumor extracapsular expansion and invasion in surrounding tissue, both crucial for staging and further treatment planning [62] . PCa aggressiveness, as classified by the GS, can also be differentiated in vivo by MRSI [63] . Nagarajan et al. found statistically significant positive correlations between metabolite ratios and surgical GS, as well as tumor volume, in the results of MRSI obtained at 1.5 T [41] . Another in vivo MRSI study in patients with biopsy-proven PCa on a 3-T scanner, followed by ex vivo HRMAS proton MRS of spatially matched tissue samples, showed strong correlations between metabolic ratios measured from in vivo and ex vivo matched spectra, as well as a correlation between GS and metabolic ratios [64] .
While the potential utility of MRSI for the PCa clinic has been demonstrated by a large number of research publications, the routine clinical adaption of MRSI has been hampered by complications in the interpretation of MRSI results. These complications can be seen in Fig. 5 . Unlike the presentations of metabolite maps previously shown for brain tumors, a spectroscopist or trained radiologist has to evaluate not only where the spectra were measured from the prostate but also the relative ratios between different metabolic regions, such as evaluations of the proposed indicator, (C+C)/C (spectral intensities of regions between creatine and choline over citrate) [41, 60, 65] .
The achievements of PCa metabolomics in studies of intact tissue present an opportunity for imaging PCa in vivo, with the reconstruction of MRSI data according to disease- Overall accuracies are presented as ROC curves for all tumors and for T2 tumors only (AUC area under curve) (adapted with permission from Wu et al. [35] , Fig. 4) specific profiles. If successful, imaging results would not only be presented as simplified maps of values of diseasespecific profiles, but would also provide more accurate assessments of the disease. This metabolomic imaging concept has been demonstrated [35] . Five whole prostates removed from patients with biopsy-proven cancer were obtained after prostatectomy and measured using multivoxel MRS on a 7-T whole-body MR scanner before whole-mount histology. Due to the lack of PCa parameters for profile constructions determined specifically for 7-T measurements, the authors tested these multivoxel MRS results with PCa metabolomic profiles obtained with intact tissue specimens measured at 14 T under HRMAS conditions, and compared the metabolomic imaging results with the whole-mount prostate histology (Fig. 6) . Using the threshold value of the median plus one standard deviation (M+SD), suggested by the intact tissue results, the study identified voxel areas that had at least two connected voxels possessing profile values higher than the M+SD determined for the particular cross-section. In the five prostates measured, 13 regions of metabolomic profiles on the analyzed cross-sections were identified as possessing values above the threshold determined for their corresponding planes. However, since M+SD values are calculated within each examined cross-section and certain voxels will possess values higher than the M+SD calculated from its given plane, disregarding the status of PCa, M+SD values are relative and difficult to compare among different planes and cases. To address this relativity, the authors defined a malignancy index (Mi p ) as the product of the sum of the profile values of the connected suspicious voxels and voxel size (in millimeters squared). The Mi p measures the absolute elevation of the metabolomic profile and may be compared among different cross-sections from different samples. The Mi p is able to discriminate PCa-positive and PCa-negative regions significantly with an overall accuracy of 93-97 % (Fig. 7) . Of interest, the report indicated that the analysis of the (C+C)/C ratios suggested by in vivo MRSI studies was not able to detect tumor regions with statistical significance, which the authors attributed to the smaller sample size used in the study than those used in in vivo MRSI [35] .
Future directions
Demonstration of the feasibility of PCa metabolomic imaging of removed prostates requires further verification and tests in larger patient populations. Moreover, translation from ex vivo to in vivo is required before metabolomic imaging can be applied by radiologists as part of a clinical examination. To achieve this, studies have to overcome the technical challenges of scanning the prostate in living human patients at 7 T [66] . Finally, testing at lower field strengths, such as 3 T and 1.5 T, should also be considered for general clinical applicability since 7 T scanners may never be universally available in most of the clinical facilities.
In addition to MRS-based PCa metabolomic imaging, MS imaging may also be a powerful tool for interrogating molecular details, according to cellular morphology, to discover biomarkers for PCa diagnosis. With recent technical advances, it has become possible to record localized MS, even with a resolution at the single-cell level, to investigate molecular spatial distributions. Matrix-assisted laser desorption ionization (MALDI) MS imaging has been reported to allow visualization of two-dimensional spatial distributions of diverse biomolecules such as proteins, peptides, lipids and sugars, which can then be compared to the histological evaluations of the same tissue. Findings of a protein expression pattern that discriminates between PCa and benign tissue indicates the potential for future discovery of PCa biomarkers as well as elucidation of PCa pathogenesis through MALDI imaging (Fig. 8 ) [67] .
In conclusion, the implementation of metabolomic imaging, either with MRS or MS, offers the potential to either identify cancer lesions to guide biopsy and evaluate cancer aggressiveness noninvasively in vivo, or increase the power of ex vivo pathological analysis. Metabolomics, in general, can provide the most representative and complete depiction of the bimolecular alterations during PCa development and progression. It is therefore one of the most promising tools for improving PCa detection and monitoring through clinical imaging. Most importantly, paradigms created for the metabolomic imaging of PCa may ultimately be applied to different tissues and organs to evaluate other human malignancies or metabolic diseases.
